Company news

Compugen Ltd. news in 2021

Compugen Ltd.'s news releases, calls and decks from 2021, newest first.

View company

Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit

December 8, 2021

Compugen Reports Third Quarter 2021 Results

November 11, 2021

Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021

November 11, 2021

Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021

November 11, 2021

Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Compared to TIGIT and PD-1 as a Novel Checkpoint on the DNAM Axis at SITC 2021

November 11, 2021

Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment

November 10, 2021

Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021

October 25, 2021

Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902

October 3, 2021

Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021

September 30, 2021

Compugen to Present at the Cantor Global Healthcare Conference

September 13, 2021

Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

August 25, 2021

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development

August 18, 2021

Compugen Reports Second Quarter 2021 Results

July 27, 2021

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207

July 18, 2021

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

July 14, 2021

Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021

July 13, 2021

Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

June 29, 2021

Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis

June 28, 2021

Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting

June 7, 2021

Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities

May 31, 2021

Compugen Reports First Quarter 2021 Results

May 12, 2021

Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series

May 10, 2021

Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen

May 9, 2021

Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021

May 2, 2021

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting

April 28, 2021

Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy

April 26, 2021

Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy

March 8, 2021

Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference

March 7, 2021

Compugen Reports Fourth Quarter and Full Year 2020 Results

February 24, 2021

Compugen Announces Data Update from COM701 Phase 1 Clinical Trial

February 24, 2021

Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®

February 21, 2021

Compugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, 2021

February 15, 2021

Calls in 2021

Decks in 2021